|Day Low/High||0.48 / 0.50|
|52 Wk Low/High||0.46 / 4.10|
Proposed Merger Will Create Clinical-Stage, Biopharmaceutical Company Focused on the Development and Commercialization of Cytisine for Smoking Cessation
The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.
Conference Call on Tuesday, August 16, 2016 at 7:30 a.m. EDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
These stocks trading for less than $10 a share are within range of triggering major breakout trades.
Data Safety Monitoring Board Recommends Continuation of Trial as Planned in Bladder Cancer Patients
Topline Results in Poor Prognosis Subpopulation Expected by End of Year
Patients More Likely to Have Treatment Resistance and Poor Prognosis
Data Presented at 2015 European Cancer Congress Includes Further Analysis from Borealis-1TM Trial of Apatorsen in Metastatic Bladder Cancer
Trade-Ideas LLC identified OncoGenex Pharmaceuticals (OGXI) as a strong on high relative volume candidate
Trade-Ideas LLC identified OncoGenex Pharmaceuticals (OGXI) as a weak on high relative volume candidate